To

TRANSMITTAL

Flease type a plussign (+) inside this bo

i;

(to be used for all correspondence after initial filing)

Application Number	10/572,563	
Filing Date	March 17, 2006	
Inventor(s)	Jiunn-Liang KO et al.	
Group Art Unit	Unassigned	
Examiner Name	Unassigned	
Attorney Docket Number	8964-000031/IIS	

	<u></u>			
ENCLOSURES (check all that apply)				
Fee Transmittal Form	Assignment Papers (for an Application)	After Allowance Communication to Group		
Fee Attached	Letter to the Official Draftsperson and Sheets of Formal Drawing(s)	LETTER SUBMITTING APPEAL BRIEF AND APPEAL BRIEF (w/clean version of pending claims)		
Amendment	Licensing-related Papers	Appeal Communication to Group (Notice of Appeal, Brief, Reply Brief)		
After Final	Petition	☐ Proprietary Information		
Affidavits/declaration(s)	Petition to Convert to a Provisional Application	Status Letter		
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address	Other Enclosure(s) (please identify below):		
Express Abandonment Request	☐ Terminal Disclaimer ☐ Request for Refund	Form PTO-1449 Copies of five (5) cited references		
Information Disclosure Statement	CD, Number of CD(s)	1,		
Certified Copy of Priority Document(s)	Remarks			
Response to Missing Parts/ Incomplete Application				
Response to Missing Parts under 37 CFR 1.52 or 1.53				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm or Hamess, Dickey & Individual name	Pierce, P.L.C. Attorney Name John A. Castellano	Reg. No. 35,094		
Signature 4	. Hoth Don No	57752		
Date May 21, 2008	W - 100)			



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/572,563

Filing Date:

March 17, 2006

Applicant:

Jiunn-Liang KO et al.

Group Art Unit:

Unassigned

Examiner:

Unassigned

Title:

FUNGAL IMMUNOMODULATORY PROTEIN (FIP)

PREPARED BY MICROORGANISMS AND USES THEREOF

Attorney Docket:

8964-000031/US

Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314 Mail Stop Amendment May 21, 2008

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS, AND OTHER INFORMATION

The patents, publications and other information submitted for consideration by the Office (except unpublished U.S. patent applications) are listed on Form PTO-1449 attached hereto.

II. <u>COPIES</u>

A. Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office; (iii) for each cited pending unpublished U.S. application listed below in Section IV, the application specification including the claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion; and (iv) all other information or that portion which caused it to be listed.

B. Any patents, publications or other information which are listed on Form PTO-1449 or on the copies of Form PTO-892, but which are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Serial Number

U.S. Filing Date

C. Because the present application was/is being filed after June 30, 2003, no copies
of the U.S. patents or U.S. patent application publications which are listed on the
attached Form PTO-1449 are enclosed pursuant to the waiver of 37 C.F.R
§ 1.98(a)(2)(i). Any foreign patent documents or non-patent literature listed on the
attached Form PTO-1449 are enclosed herewith.
D. This is a PCT application in the entry of the National Phase in the United States

D. This is a PCT application in the entry of the National Phase in the United States. A copy of the International Search Report is attached for the Examiner's information. The documents listed on the International Search Report are listed on the attached Form PTO-1449 for consideration by the Examiner and for listing on any patent resulting from this application. Since the International Search Report was from the US, EPO, or JPO search authorities, copies of these references should have been supplied to the USPTO under the trilateral agreement and are believed to be in the file of the above-identified application. (MPEP 1893.03(g))

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

- A. \(\sum \) Except as may be indicated below in (B), all of the patents, publications or other information are in the English language (concise explanation not required).
- B. \boxtimes A concise explanation of the relevance of each patent, publication or other information listed that is not in the English language is as follows (see 37 C.F.R. § 1.98(a)(3)):
 - 1. See the attached foreign patent office communication from a counterpart foreign application: European Search Report dated November 5, 2007 in corresponding European Application No. EP 04762178.4
 - 2. English abstracts are provided for: KR 04-019423 and JP 06-283244
 - 3. Other:
- C. The following additional information is provided for the Examiner's consideration. The following references cited in the attached corresponding Search Report are not submitted because they were previously submitted in an Information Disclosure Statement filed February 1, 2007: (1) Murasugi A, et al., Molecular Cloning of a cDNA and a Gene Encoding an Immunomodulatory Protein, Ling Zhi-8, from a Fungus, Ganoderma lucidum, J. Biol. Chem., 266:2486-93 (1991); (2) Ko JL et al., A New Fungal Immunomodulatory Protein, FIP-FE Isolated from the Edible Mushroom, Flammulina Velutipes and its Complete Amino Acid Sequence," Eur. J. Biochem., Vol. 228, No. 2, pp. 224-49 (1995); and (3) Kohsuke Kino et al., "Isolation and characterization of a new immunomodulatory protein, Ling Zhi-8 (LZ-8), from Ganoderma lucidium," J. Biol. Chem., vol. 264, no. 1, pp. 472-78 (1989-01-05).

IV. CROSS REFERENCE TO RELATED APPLICATION(S)

U.S. Application No. 10/572,563 Attorney Docket No. 8964-000031/US Page 3 of 5

A. The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this(these) application(s) to the Examiner's attention, Applicant(s) does(do) not waive the confidentiality provisions of 35 U.S.C. § 122.			
	Serial No.	Filing Date	Art Unit
THIS	IDS IS BEING FILED UNDI	<u>ER</u>	
A. 🔀	A. X 37 C.F.R. § 1.97(b): (check only one box)		
		the filing date of a national application under 37 C.F.R. §	
		f the date of entry of the national rnational application (37 C.F.) ed.	
	§ 1.97(b)(3)). No fee or cert Action on the merits has been § 1.97(c) and see the certif	f a first Office Action on the extification is required. In the exen issued, please consider this fication under 37 C.F.R. § 1.9, charge our deposit account a C.F.R. § 1.17(p).	rent that a first Office IDS under 37 C.F.R. 7(e) below; or, if no
		a first Office Action after the feer 37 C.F.R. § 1.114. No fee	
В.	37 C.F.R. § 1.97(c): (check o	only one box)	
		of either any Final Office Actance under 37 C.F.R. § 1.31	
	1. No certification; there 37 C.F.R. § 1.17(p).	fore, a fee in the amount of \$1	180.00 is required by
	2. See the certification b	elow. No fee is required.	
C. 🔲	37 C.F.R. § 1.97(d):		
		either a Final Office Action und oder 37 C.F.R. § 1.311, yet on	

V.

U.S. Application No. 10/572,563 Attorney Docket No. 8964-000031/US Page 4 of 5

	1. See the certification below. A fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
VI.	CERTIFICATION UNDER 37 C.F.R. § 1.97(e): (check only one box)
	The undersigned hereby certifies that:
	A. each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(1)). See further statement under 37 C.F.R. § 1.704(d) below in section VII, if applicable; or
	B. no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(2)).
	C. Some of the items of information were first cited in a communication from a foreign patent office. As to this information, the undersigned hereby certifies that each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS.
VII.	STATEMENT UNDER 37 C.F.R. § 1.704(d)
	The undersigned hereby states that:
	each item of information contained in this IDS was cited in a communication from a patent office in a counterpart application and this communication was not received by lividual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this
VIII.	PAYMENT OF FEES (check only one box)
	A. \boxtimes No fee is believed to be due in light of the above-noted status or above-provided certification.
	B. A check in the amount of \$180.00 is enclosed for the above-identified fee.

U.S. Application No. 10/572,563
Attorney Docket No. 8964-000031/US
Page 5 of 5

C. Please charge Deposit Account No. 08-0750 in the amount of \$180.00 for the above-indicated fee. A duplicate copy of this paper is attached.

The above references are being cited only in the interest of candor and without any admission that they constitute statutory prior art, contain matter which anticipates the invention, or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art. Furthermore, this Information Disclosure Statement shall not be construed as a representation that a search has been made.

If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 08-0750.

Please charge any additional fees or credit any overpayment pursuant to 37 C.F.R. §§ 1.16 or 1.17 to Deposit Account No. 08-0750.

Respectfully submitted,

HARNESS, DICKEY, & PIERCE, P.L.C.

Registration No. 35,0

P.O. Box 8910

Reston, Virginia 20195 (703) 668-8000

Enclosures:	\boxtimes	Form PTO-1449(s) (1 sheet(s))
	\boxtimes	Documents
	\boxtimes	European Search Report dated November 5, 2007 in corresponding
		European Application No. EP 04762178.4
		Fee
		Other: